Is larotrectinib a targeted drug?

Larotrectinib is a targeted therapy drug. It is a tyrosine kinase inhibitor and is mainly used to treat malignant tumors carrying NTRK gene fusions. NTRKGene fusion is a specific genetic variation in tumor cells involving the nerve growth factor receptor (Neurotrophic Tyrosine Receptor Kinase, NTRK) gene. This fusion results in abnormal tyrosine kinase activity that drives tumor cell growth and spread. Larotrectinib specifically inhibits NTRK kinase activity, thereby blocking this abnormal signaling pathway in a targeted manner and producing anti-cancer effects on tumor cells. Due to its targeted nature, larotrectinib has shown significant efficacy in specific patient populations, providing a promising treatment option for this group of patients.